NCT00376324View on ClinicalTrials.gov

Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Healthy Subjects
Interventions
DRUG

Tigecycline

Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.

Trial Locations (1)

85006

Phoenix

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00376324 - Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone | Biotech Hunter | Biotech Hunter